Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Amanda Pifano Soares FerreiraFernanda Salles SeguroAndre Ramires Neder AbdoFernanda Maria SantosFelipe Vieira Rodrigues MacielLuciana NardinelliRicardo Rodrigues GiorgiAntonio Roberto Lancha RuizMilton Pifano Soares FerreiraEduardo Magalhaes RegoVanderson RochaIsrael BenditPublished in: Annals of hematology (2023)
The results presented are similar to those described in prospective and randomized trials, demonstrating that the outcomes are reproducible in the real world. EMR at 3 and 6 months reflects better long-term responses, including higher rates of deeper molecular responses. Considering treatment costs, the absence of literature evidence of an impact on overall survival demonstrated by first-line second-generation tyrosine kinase inhibitors (TKIs), and the global OS of 85.8%, imatinib mesylate (IM) is still an excellent therapeutic option.